Interleukin‐17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases
- 20 February 2019
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 46 (5), 426-430
- https://doi.org/10.1111/1346-8138.14815
Abstract
Palmoplantar pustular psoriasis, also termed palmoplantar pustulosis (PPP), is a rare disease affecting the palmoplantar regions characterized by sterile, yellow to brown pustules mostly on erythematous skin. PPP is related to a high burden due to painful, impaired and stigmatizing character. Several isoforms of interleukin (IL) have been implicated in its pathophysiology. Here, we report on four patients with PPP treated with the novel IL‐17 receptor A blocker brodalumab, in whom this therapy was not successful or showed moderate improvement combined with adverse events.Keywords
This publication has 10 references indexed in Scilit:
- No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasisJournal of Dermatological Treatment, 2018
- Successful treatment of palmoplantar pustular psoriasis with brodalumabEuropean Journal Of Dermatology, 2018
- Brodalumab‐induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasisThe Journal of Dermatology, 2018
- Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapiesJournal of the American Academy of Dermatology, 2018
- Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disordersExpert Opinion on Biological Therapy, 2017
- Palmoplantar pustulosis – a cross-sectional analysis in GermanyDermatology Online Journal, 2017
- Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label studyBritish Journal of Dermatology, 2016
- Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese studyThe Journal of Dermatology, 2016
- Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasisJournal of the European Academy of Dermatology and Venereology, 2014
- Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serumExperimental Dermatology, 2011